Skip to main content

Medication Treatments

With the lethality, availability and use of stimulants all greatly increasing in the U.S. in recent years and the COVID-19 pandemic complicating the treatment landscape for patients and practitioners alike, it’s critical for providers to weather the storm, Deni Carise, PhD, chief science officer for Recovery Centers of America, told Cocaine, Meth & Stimulant Summit attendees in a Saturday session.
The Indiana University School of Medicine has received a $12.3 million grant from the National Institute on Drug Abuse for a two-stage research project to study the use of tezampanel to treat opioid withdrawal syndrome, as well as other addictions and mental illnesses.
Cordant Health Solutions has added a pharmacy in Mesa, Arizona, that will collaborate with clinicians in OBOT settings to deliver medicines to patients during their office visits.
Half of clinicians who are waivered to prescribe buprenorphine for the treatment of opioid use disorder have actually done so, and a majority are prescribing the medication for a number of patients that is well below the limit for which they are waivered, according to a new study.
A study using trained actors attempting to get addiction treatment in 10 states found that pregnant women were about 20% less likely to be accepted for treatment vs. women who are not pregnant, with the largest discrepancy involving buprenorphine prescribers.
Back to Top